FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
30/11/2024
Voltar para busca
Dado oficial do USPTO
CHIRAL CQ QUEST
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
39
Atualização mais recente
30/11/2024
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
1, 5, 40
Data de depósito
02/09/2022
Data de registro
28/05/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
28/05/2024
Última transação
28/05/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
CN
Examinador
RIEPEL, CHRISTINA
Unidade examinadora
N60
Localização atual
FILE REPOSITORY (FRANCONIA)
Descrição da marca
The mark consists of the capitalized words "CHIRAL QUEST" with a diamond-shaded figured formed by the letters "C" and "Q" at the center. The left part of the figure is a solid black line, and the right part of the figure is a black and white stripe.
Titulares e representantes
Titulares
Chiral Quest (Suzhou) Co., Ltd.
Representantes
Richard A. Arrett Vidas, Arrett & Steinkraus, P.A.
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 40
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Hydrochlorates; benzene derivatives being industrial chemicals; p-aminophenol; agricultural chemicalsexcept fungicidesherbicidesinsecticides and parasiticides; chemical substances for analyses in laboratoriesother than for medical or veterinary purposes; catalysts for oxidation process; biochemical catalysts; chemical preparations for scientific purposesother than for medical or veterinary use; chemical preparations for analyses in laboratoriesother than for medical or veterinary purposes; catalysts for chemical and biochemical processes
Classe 5
Medicines for human purposes for treatment of vascular diseasesdiabetes and infectious diseasesfor use in the treatment of diseases and disorders in the fields of oncologycardiologyimmunologyneurology; pharmaceutical preparations for treatment of vascular diseasesdiabetes and infectious diseasesfor use in the treatment of diseases and disorders in the fields of oncologycardiologyimmunologyneurology; chemico-pharmaceutical preparations for treatment of vascular diseasesdiabetes and infectious diseasesfor use in the treatment of diseases and disorders in the fields of oncologycardiologyimmunologyneurology; drugs for medical purposes for treatment of vascular diseasesdiabetes and infectious diseasesfor use in the treatment of diseases and disorders in the fields of oncologycardiologyimmunologyneurology; biological preparations for medical purposes for treatment of vascular diseasesdiabetes and infectious diseasesfor use in the treatment of diseases and disorders in the fields of oncologycardiologyimmunologyneurology; amino acids for medical purposes for treatment of vascular diseasesdiabetes and infectious diseasesfor use in the treatment of diseases and disorders in the fields of oncologycardiologyimmunologyneurology; active pharmaceutical ingredientnamely amino acids derivativeschiral or heterocyclic molecular derivatives for medical purposes; chemical reagents for medical or veterinary purposes for treatment of vascular diseasesdiabetes and infectious diseasesfor use in the treatment of diseases and disorders in the fields of oncologycardiologyimmunologyneurology; chemical preparations for medical purposes for treatment of vascular diseasesdiabetes and infectious diseasesfor use in the treatment of diseases and disorders in the fields of oncologycardiologyimmunologyneurology; chemical preparations for pharmaceutical purposes for treatment of vascular diseasesdiabetes and infectious diseasesfor use in the treatment of diseases and disorders in the fields of oncologycardiologyimmunologyneurology
Classe 40
Recycling of chemicals; water treating; cryopreservation services; medicinal materials processingnamely processing of amino acids derivativeschiral or heterocyclic molecular derivatives; chemical processing
Publicações
Histórico de despachos e eventos da marca no USPTO.
39 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/11/2024
FIMP
FINAL DISPOSITION PROCESSED
10/11/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
28/08/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
28/05/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
28/05/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
21/05/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/05/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
01/05/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/03/2024
PUBO
PUBLISHED FOR OPPOSITION
12/03/2024
GPNX
NOTIFICATION PROCESSED BY IB
11/03/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
21/02/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
21/02/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
21/02/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
21/02/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
30/01/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
30/01/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
30/01/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
30/01/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
30/01/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
29/01/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
29/01/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
29/01/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
29/01/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
29/01/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
29/01/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
29/01/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
29/01/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
29/01/2024
RFNT
REFUSAL PROCESSED BY IB
21/08/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/08/2023
RFRR
REFUSAL PROCESSED BY MPU
03/08/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
27/06/2023
CNRT
NON-FINAL ACTION WRITTEN
26/06/2023
DOCK
ASSIGNED TO EXAMINER
20/06/2023
MAFR
APPLICATION FILING RECEIPT MAILED
06/12/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/12/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/12/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CHIRAL CQ QUEST ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.